What is the recommended treatment for recurrent pericarditis?

Treatment of Recurrent Pericarditis

First-line treatment for recurrent pericarditis is aspirin or NSAIDs at full doses combined with colchicine (0.5 mg twice daily for ≥70 kg, 0.5 mg once daily for <70 kg) for at least 6 months, plus exercise restriction until symptom resolution and CRP normalization. 1

Stepwise Treatment Algorithm

First-Line Therapy (Class I, Level A)

• Aspirin 500-1000 mg every 6-8 hours (1.5-4 g/day total) OR
• Ibuprofen 600 mg every 8 hours (1200-2400 mg/day) OR
• Indomethacin 25-50 mg every 8 hours

PLUS

• Colchicine 0.5 mg twice daily (≥70 kg) or 0.5 mg once daily (<70 kg) for minimum 6 months 1
• Consider extending colchicine beyond 6 months based on clinical response (Class IIa) 1
• Provide gastroprotection with all NSAIDs 1

PLUS

• Exercise restriction until symptoms resolve and CRP normalizes
  • Non-athletes: Until symptom resolution and CRP normalization 1
  • Athletes: Minimum 3 months until symptoms, CRP, ECG, and echocardiogram normalize 1

Monitoring and Tapering

• Use CRP to guide treatment duration (Class IIa) 1
• Taper NSAIDs gradually after symptom resolution and CRP normalization:
  • Aspirin: Decrease by 250-500 mg every 1-2 weeks 1
  • Ibuprofen: Decrease by 200-400 mg every 1-2 weeks 1
• Stop one drug class at a time during tapering 1

Second-Line Therapy: Low-Dose Corticosteroids

Use ONLY when:

• Contraindications to aspirin/NSAIDs/colchicine exist (true allergy, recent GI bleeding, high bleeding risk on anticoagulation) 1
• Incomplete response to first-line therapy after adequate trial
• Infectious causes have been excluded 1
• Specific indications present (autoimmune disease, pregnancy, post-pericardiotomy syndrome) 1

Dosing:

• Prednisone 0.25-0.5 mg/kg/day (avoid higher doses) 1
• Maintain until symptom resolution and CRP normalization
• Taper extremely slowly (critical threshold is 10-25 mg/day where recurrences spike) 1:

  • 50 mg: Decrease 10 mg every 1-2 weeks

  • 50-25 mg: Decrease 5-10 mg every 1-2 weeks
  • 25-15 mg: Decrease 2.5 mg every 2-4 weeks
  • <15 mg: Decrease 1.25-2.5 mg every 2-6 weeks 1

Bone protection during corticosteroid use:

• Calcium 1200-1500 mg/day + Vitamin D 800-1000 IU/day for all patients
• Bisphosphonates for men ≥50 years and postmenopausal women on ≥5-7.5 mg/day prednisone 1

Critical Pitfall: Corticosteroid Management

Corticosteroids are NOT recommended as first-line therapy (Class III, Level B) 1. They promote chronicity, increase recurrence rates (up to 50% after first recurrence), and create steroid dependence 1. If symptoms recur during tapering, do NOT increase corticosteroid dose—instead maximize aspirin/NSAID dosing (every 8 hours, IV if needed), ensure colchicine is added, and use analgesics for pain control 1.

Third-Line Therapy: IL-1 Inhibitors and Immunosuppressants

For corticosteroid-dependent recurrent pericarditis not responsive to colchicine (Class IIb) 1:

IL-1 Pathway Inhibitors (Preferred):

• Anakinra or Rilonacept (FDA-approved for recurrent pericarditis)
• Recent evidence shows IL-1 inhibitors increasingly replace corticosteroids as second-line therapy, with 64% of patients receiving IL-1 inhibitors by 2023 vs. 33% receiving corticosteroids 2
• Only 5% of patients starting rilonacept subsequently required corticosteroids >30 days 2
• Effective in reducing recurrences and allowing corticosteroid withdrawal in inflammatory phenotypes 3, 4

Alternative Immunosuppressants:

• Azathioprine (most commonly used conventional agent, 44% of cases) 5
• Methotrexate (25% of cases) 5
• IVIG (intravenous immunoglobulin)

These require multidisciplinary consultation with immunologists/rheumatologists and patient education about immunosuppression risks 1. Conventional immunosuppressants achieve clinical resolution in published reports and facilitate corticosteroid withdrawal in 72% of patients, with only 10% recurrence rate 5.

Fourth-Line: Pericardiectomy

• Last resort only after thorough trial of unsuccessful medical therapy 1
• Refer to center with specific surgical expertise
• Reserved for refractory cases or development of constrictive pericarditis 6

Key Clinical Pearls

Recurrence Prevention:

• Colchicine reduces recurrence rate by 50% (from 30-50% to 15-25%) 7
• Inadequate treatment of first episode is a common cause of recurrence 1
• Corticosteroid use and rapid tapering (<1 month) increase recurrence risk 3

Prognosis Reassurance:

• Severe complications are uncommon in idiopathic recurrent pericarditis
• Cardiac tamponade is rare
• Constrictive pericarditis occurs in <1% of idiopathic cases 1
• Complication rates relate to etiology, not number of recurrences 1

Emerging Paradigm Shift:

• Recognition of recurrent pericarditis as autoinflammatory, IL-1-mediated disease in substantial proportion of patients 8
• IL-1 inhibitors now allow rapid symptom control, corticosteroid withdrawal, and marked reduction in recurrences 8, 9
• Most patients starting second-line corticosteroids (59%) eventually transition to IL-1 inhibitors 2